natgillin/translations-raw huggingface dataset:
Patients should be monitored for the development or worsening of proteinuria during ramucirumab therapy.
Med zdravljenjem z ramucirumabom spremljajte bolnike in bodite pozorni na razvoj ali poslabšanje proteinurije.
Patients should be monitored for the development, or worsening of proteinuria during ramucirumab therapy.
Med zdravljenjem z ramucirumabom je treba bolnike spremljati in biti pozorni na razvoj ali poslabšanje proteinurije.
Patients should be monitored for: thromboembolic events, peripheral neuropathy, rash/skin reactions, bradycardia, syncope, somnolence, neutropenia and thrombocytopenia (see sections 4.4 and 4.8).
Bolnike je treba nadzorovati za: trombembolične dogodke, periferno nevropatijo, izpuščaje/kožne reakcije, bradikardijo, sinkopo, somnolenco, nevtropenijo in trombocitopenijo (glejte poglavji 4.4 in 4.8).
Patients should be monitored until symptoms resolve.
Bolnike nadzorujemo, dokler simptomi ne prenehajo.
Patients should be monitored with liver laboratory tests (including ALT, AST and total bilirubin) prior to the start of treatment, every 2 weeks for the first month of treatment and monthly thereafter.
Pri bolnikih je treba spremljati laboratorijske vrednosti jetrnih testov (vključno z vrednostmi ALT, AST in celokupnega bilirubina) pred začetkom zdravljenja, vsaka 2 tedna v prvem mesecu zdravljenja in nato enkrat mesečno.
Patients should be observed by the physician for immediate toxic reactions.
Zdravniki morajo bolnike opazovati, zaradi možnosti takojšnjih toksičnih reakcij.
Patients should be observed for signs and symptoms of heart failure, weight gain and oedema when pioglitazone is used in combination with insulin.
Če se pioglitazon uporablja v kombinaciji z insulinom, je treba bolnike nadzirati glede pojava znakov in simptomov srčnega popuščanja, povečanja telesne mase ali edemov.
Patients should be observed for signs and symptoms of hepatic dysfunction when Zinbryta is used concomitantly with other hepatotoxic medicinal products.
Pri bolnikih je treba opazovati pojav znakov in simptomov motnje delovanja jeter, če se zdravilo Zinbryta uporablja sočasno z drugimi hepatotoksičnimi zdravili.
Patients should be premedicated with corticosteroids immediately prior to LEMTRADA infusion for the first 3 days on any treatment course.
Bolnike je treba premedicirati s kortikosteroidi tik pred infuzijo zdravila LEMTRADA prve tri dni vsakega postopka zdravljenja.
Patients should be prescribed an initial titration supply of one bottle (2 sprays or 8 sprays) of PecFent 100 micrograms/spray.
Bolnikom predpišemo začetno količino za titracijo, ki je ena steklenica (2 vpiha ali 8 vpihov) zdravila PecFent 100 mikrogramov/vpih.
Patients should be provided with information from the Package Leaflet to increase their awareness of potential serious infections and the signs and symptoms of them.
Bolnike je treba seznaniti z informacijami, ki so v navodilih za uporabo, da bi tako povečali njihovo pozornost za potencialno resne okužbe ter njihove znake in simptome.
Patients should be re-hydrated before the administration.
Bolnike je treba pred uporabo
Patients should be re-informed about the risk factors for PML, like duration of treatment, immunosuppressant use prior to receiving TYSABRI and the presence of anti- John Cunningham virus (JCV) antibodies (see section 4.4.).
Bolnika je treba ponovno informirati o dejavnikih tveganja za PML, kot so trajanje zdravljenja, uporaba imunosupresivov pred prejemanjem zdravila TYSABRI in prisotnost protiteles proti virusu John Cunningham (JCV) (glejte poglavje 4.4).
Patients should be reassessed regularly by their prescriber/health care provider so that the dose of BiResp Spiromax remains optimal.
Zdravljenje bolnikov mora redno ovrednotiti zdravnik , ki predpisuje zdravilo, tako da odmerek zdravila BiResp Spiromax ostane optimalen.
Patients should be reassessed regularly by their prescriber/health care provider so that the dose of Budesonide/Formoterol Teva remains optimal.
Zdravljenje bolnikov mora redno ovrednotiti zdravnik , ki predpisuje zdravilo, tako da odmerek zdravila Budezonid/formoterol Teva ostane optimalen.
Patients should be reassessed regularly by their prescriber/health care provider so that the dose of DuoResp Spiromax remains optimal.
Zdravljenje bolnikov mora redno ovrednotiti zdravnik , ki predpisuje zdravilo, tako da odmerek zdravila DuoResp Spiromax ostane optimalen.
Patients should be reassessed regularly by their prescriber/healthcare provider so that the dose of BiResp Spiromax remains optimal.
Zdravnik , ki predpisuje zdravilo, mora bolnike redno ocenjevati, tako da odmerek zdravila BiResp Spiromax ostane optimalen.
Patients should be reassessed regularly by their prescriber/healthcare provider so that the dose of Budesonide/Formoterol Teva Pharma B.V. remains optimal.
Zdravnik , ki predpisuje zdravilo, mora bolnike redno ocenjevati, tako da odmerek zdravila Budezonid/formoterol Teva Pharma B.V. ostane optimalen.
Patients should be reassessed regularly by their prescriber/healthcare provider so that the dose of DuoResp Spiromax remains optimal.
Zdravnik , ki predpisuje zdravilo, mora bolnike redno ocenjevati, tako da odmerek zdravila DuoResp Spiromax ostane optimalen.
Patients should be regularly assessed by a doctor to ensure that they receive the lowest dose sufficient to control symptoms.
Bolnike mora redno pregledovati zdravnik, ki poskrbi za to, da prejemajo najmanjši zadosten odmerek za nadzor simptomov.
Patients should be regularly assessed by a doctor to ensure that they receive the lowest dose sufficient to control symptoms.
Bolnike mora redno pregledovati zdravnik, ki poskrbi za to, da prejemajo najmanjši zadostni odmerek za nadzor simptomov.
Patients should be reminded to take their Budesonide/Formoterol Teva Pharma B.V. maintenance dose as prescribed, even when asymptomatic.
Bolnike je treba opozoriti, naj uporabljajo vzdrževalni odmerek zdravila Budezonid/formoterol Teva Pharma B.V. skladno z navodili zdravnika, tudi če nimajo simptomov.
Patients should be retreated with docetaxel when neutrophils recover to a level ≥ 1,500 cells/mm3 (see section 4.2).
3 docetaksel spet dobiti, šele ko se število nevtrofilcev znova zveča na vrednost ≥ 1.500 celic/mm (glejte poglavje 4.2).
Patients should be retreated with docetaxel when neutrophils recover to a level ≥1,500 cells/mm3 (see section 4.2).
Bolniki smejo docetaksel spet dobiti šele, ko se število nevtrofilcev znova poveča na vrednost ≥ 1500 celic/mm3 (glejte poglavje 4.2).
Patients should be reviewed regularly while on therapy for any signs or symptoms that might represent myopathy.
Bolnike je treba med zdravljenjem redno pregledovati, da opazimo kakršne koli znake ali simptome, ki bi lahko predstavljali miopatijo.
Patients should be stable on alpha-blocker therapy prior to initiating Spedra.
pred začetkom uporabe zdravila Spedra mora biti zdravstveno stanje bolnikov, ki jemljejo zaviralce receptorjev alfa, stabilno.
Patients should be started with a dose of 45 mg in the morning and 15 mg in the evening (45+15 mg), and the dose should then be increased to 60+30 mg or 90+30 mg, depending on what the patient can tolerate.
Bolniki morajo na začetku jemati odmerek 45 mg zjutraj in 15 mg zvečer (45
Patients should be supine with the head positioned to centre the brain, including the cerebellum, in the PET scanner field of view.
Bolniki morajo ležati na hrbtu, glava pa mora biti v položaju, ki možgane, vključno z malimi možgani, postavlja v središče vidnega polja aparata za PET.
Patients should be supine with the head positioned to centre the brain, including the cerebellum, in the PET scanner field of view.
Bolniki morajo ležati na hrbtu, glava pa mora biti v položaju, v katerem so možgani, vključno z malimi možgani, v vidnem polju aparata za PET.
Patients should be tested for HBV infection before initiating treatment with Benepali.
Pred uvedbo zdravljenja z zdravilom Benepali je treba bolnike preiskati na okužbo s HBV.
Patients should be tested for HBV infection before initiating treatment with Cimzia.
Pred začetkom zdravljenja z zdravilom Cimzia je treba bolnike testirati na okužbo s HBV.
Patients should be tested for HBV infection before initiating treatment with Enbrel.
Pred uvedbo zdravljenja z zdravilom Enbrel je treba bolnike preiskati na okužbo s HBV.
Patients should be tested for HBV infection before initiating treatment with Inflectra.
Pred začetkom zdravljenja z zdravilom Inflectra, morate bolnike testirati na okužbo z virusom hepatitisa B (HBV).
Patients should be tested for HBV infection before initiating treatment with Remsima.
Pred začetkom zdravljenja z zdravilom Remsima, morate bolnike testirati na okužbo z virusom hepatitisa B (HBV).
Patients should be tested for HBV infection before initiating treatment with Simponi.
Pred začetkom zdravljenja z zdravilom Simponi, se morajo bolniki testirati na okužbo z virusom hepatitisa B (HBV).
Patients should be told about the signs and symptoms of GI undesirable effects and what steps to take if they occur. (See section 4.8.)
Bolnike je potrebno seznaniti z znaki in simptomi neželenih gastrointestinalnih učinkov in jim povedati, kako naj ukrepajo, če bi se ti pojavili (glejte poglavje 4.8).
Patients should be told about the signs and symptoms of GI undesirable effects and what steps to take if they occur. (See section 4.8.)
Bolnike je potrebno seznaniti z znaki in simptomi neželenih gastrointestinalnih učinkov in jim povedati, kako naj ukrepajo, če bi se ti pojavili. (Glejte poglavje 4.8)
Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel (alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician.
Bolniki morajo biti obveščeni, da je lahko čas, potreben za zaustavitev krvavitve, daljši kot ponavadi, ko jemljejo klopidogrel (sam ali v kombinaciji z ASA) in da morajo poročati svojemu zdravniku o kakršni koli neobičajni krvavitvi (mesto ali trajanje).
Patients should be trained on how to inject themselves.
Bolnike je treba naučiti, kako si lahko sami injicirajo zdravilo.
Patients should be treated until disease progression or unacceptable toxicity.
Bolnike se zdravi do napredovanja bolezni ali nesprejemljive toksičnosti.
Patients should be treated with Perjeta and trastuzumab until disease progression or unmanageable toxicity.
Bolnike je treba z zdravilom Perjeta in trastuzumabom zdraviti do napredovanja bolezni ali pojava neobvladljivih toksičnih učinkov.
Patients should be up-titrated using 2 mg doses no faster than every 2 weeks based on tolerability and effectiveness.
Odmerek za bolnika je treba vsaka 2 tedna povečati za 2 mg glede na prenašanje in učinkovitost.
Patients should be warned about
Bolnike je treba opozoriti na te
Patients should be warned about the potential for dizziness and somnolence (see section 4.8) and should be advised not to drive or operate machines if any of these symptoms occur.
Bolnike je treba opozoriti na morebitno omotico in somnolenco (glejte poglavje 4.8) in jim svetovati, naj ne vozijo ali upravljajo strojev, če se pojavi kateri koli od teh simptomov.
Patients should be warned of the possibility of long term side effects, especially photosensitivity, and the need to seek medical assistance if they arise.
Bolnike je treba opozoriti na možnost dolgotrajnih neželenih učinkov, posebno preobčutljivosti na svetlobo, in poučiti, da v takih primerih poiščejo zdravstveno pomoč.
Patients should be warned to avoid grapefruit juice beverages while taking dronedarone.
Bolnike je treba opozoriti, naj se med jemanjem dronedarona izogibajo napitkom z grenivkinim sokom.
Patients should brush their teeth thoroughly twice daily and have regular dental examinations.
Bolniki si morajo temeljito ščetkati zobe dvakrat
Patients should check that the control window is green.
Bolniki morajo preveriti, ali se je obarvano kontrolno okence spremenilo v zelenega.
Patients should commence treatment with a fixed- dose combination containing a lower dose of the corticosteroid component and will then be titrated up in respect of the corticosteroid dose until control of asthma is achieved.
Bolniki naj zdravljenje začnejo s fiksno kombinacijo odmerka, ki vsebuje manjši odmerek sestavine kortikosteroida, nato pa se odmerek kortikosteroida povečuje, dokler ni dosežen nadzor nad astmo.
Patients should consult a physician before taking alli concomitantly with antiretroviral medications.
Pred sočasnim jemanjem zdravila alli in protiretrovirusnih zdravil se naj bolniki posvetujejo z zdravnikom.
Patients should drink plenty of water while on treatment.
Bolniki morajo med zdravljenjem piti veliko vode.
Patients should establish a convenient daily schedule of drug intake and maintain a steady temporal relationship with food intake.
Bolniki naj vzpostavijo primeren dnevni razpored vnosa zdravila in vzdržujejo stalno časovno razmerje med jemanjem zdravila in obroki.
Patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that ADENURIC does not adversely affect performance.
Bolniki morajo biti pred vožnjo, uporabo strojev ali udeležbo v tveganih dejavnostih previdni, dokler niso povsem prepričani, da zdravilo ADENURIC ne vpliva negativno na opravljanje teh dejavnosti.
Patients should have either:
Bolniki so pred tem:
Patients should have had a life expectancy of  12 weeks and no prior radiotherapy to the pelvis or abdomen.
Bolnice so morale imeti pričakovano preživetje  12 tednov in v preteklosti niso smele prejeti radioterapije medenice ali trebuha.
Patients should have their serum creatinine levels assessed prior to each dose of zoledronic acid.
Bolnikom je treba pred vsakim odmerkom zdravila Zoledronska kislina Mylan določiti vrednost serumskega kreatinina.
Patients should hold the Genuair inhaler horizontally with the mouthpiece towards them and the orange button facing straight up.
Bolniki naj inhalator Genuair držijo vodoravno, tako da bo ustnik obrnjen proti njim, oranžni gumb pa bo obrnjen naravnost navzgor.
Patients should inform physicians and dentists that they are taking Clopidogrel/Acetylsalicylic acid Zentiva before any surgery is scheduled and before any new medicinal product is taken.
Bolniki morajo obvestiti zdravnika in zobozdravnika, da jemljejo zdravilo Klopidogrel/acetilsalicilna kislina Zentiva , pred vsakim načrtovanjem kirurškega posega in preden vzamejo katerokoli novo zdravilo.
Patients should inform their doctor before they start treatment if they have severe hepatic disease.
Bolniki morajo zdravnika pred pričetkom zdravljenja obvestiti o morebitni hudi okvari jeter.
Patients should keep breathing in, even after they have heard the inhaler "click".
Bolniki morajo z vdihovanjem nadaljevati, tudi če že zaslišijo »klik« inhalatorja.
Patients should keep to their prescribed low- phosphate diets.
Bolniki se morajo držati predpisane diete z majhnim vnosom fosfatov.
Patients should keep to their prescribed low-phosphate diets.
Bolniki se morajo držati predpisane diete z majhnim vnosom fosfatov.
Patients should maintain adequate hydration while taking ataluren.
Zato morajo bolniki med jemanjem atalurena poskrbeti za zadostno hidracijo.
Patients should not be initiated on Aerivio Spiromax during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma.
V obdobju poslabšanja astme in pri močnem ali akutnem poslabšanju astme se zdravljenja z zdravilom Aerivio Spiromax ne sme uvesti.
Patients should not be initiated on Aerivio Spiromax during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma.
V obdobju poslabšanja astme in pri močnem ali akutnem poslabšanju astme se zdravljenja z zdravilom Airexar Spiromax ne sme uvesti.
Patients should not be initiated on Budesonide/Formoterol Teva Pharma B.V. during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma.
Bolnikom se ne sme uvesti zdravila Budezonid/formoterol Teva Pharma B.V. med poslabšanjem astme ali v obdobju pomembnega oziroma akutnega poslabšanja simptomov astme.
Patients should not be retreated with subsequent cycles of Abraxane until neutrophils recover to >1500 cells/mm3 and platelets recover to >100,000 cells/mm3 (see section 4.2).
Nadaljnjih ciklov zdravila Abraxane ne smete začeti, dokler se nevtrofilci ne vrnejo na vrednost > 1.500 celic/mm3, trombociti pa na vrednost > 100.000 celic/mm3 (glejte poglavje 4.2).
Patients should not be retreated with subsequent cycles of docetaxel until neutrophils recover to a level
Bolniki ne smejo znova dobiti ciklusov docetaksela, dokler se število nevtrofilcev ne poveča na
Patients should not be retreated with subsequent cycles of docetaxel until neutrophils recover to a level
znova dobiti ciklusov docetaksela, dokler se število nevtrofilcev ne poveča na > 1.500 celic/mm in
Patients should not be switched from a free co-administration of fenofibrate and pravastatin preparation to Pravafenix (see section 5.2.).
Bolniki ne smejo prehajati s sočasne uporabe zdravil s fenofibratom in pravastatinomna zdravilo Pravafenix (glejte poglavje 5.2).
Patients should not be tested for anti-JCV antibodies within 2 weeks of PLEX due to removal of antibodies from the serum, or within 6 months of IVIg (i.e.
Bolnikov ne testirajte za serumska protitelesa proti JCV prej kot 2 tedna po PLEX zaradi odstranitve protiteles iz seruma ali prej kot 6 mesecev po IVIg (t.j.
Patients should NOT be treated with porfimer if:
Bolnikov se NE sme zdraviti s porfirini, če:
Patients should not chew , suck or crush the tablet because of a potential for oropharyngeal ulceration.
Bolnik tablete ne sme žvečiti, sesati ali drobiti, ker obstaja nevarnost za nastanek razjede v ustih in žrelu.
Patients should not chew or suck the tablet, because of a potential for oropharyngeal ulceration
Bolniki tablet ne smejo žvečiti ali sesati, ker lahko pride do ulceracije žrela.
Patients should not chew or suck the tablet, because of a potential for oropharyngeal ulceration.
Bolnik tablete ne sme žvečiti ali sesati, ker obstaja nevarnost za nastanek razjede v ustih in žrelu.
Patients should not chew or suck the tablet, because of a potential for oropharyngeal ulceration.
Bolniki tablet ne smejo žvečiti ali sesati, ker lahko pride do ulceracije žrela.
Patients should not chew, suck or crush the tablet because of a potential for oropharyngeal ulceration.
Bolniki tablet ne smejo žvečiti, sesati ali drobiti ker se lahko pojavi ulceracija žrela.
Patients should not chew, suck or crush the tablet because of a potential for oropharyngeal ulceration.
Bolniki tablet ne smejo žvečiti, sesati ali drobiti, ker se lahko pojavi ulceracija žrela.
Patients should not donate blood or semen during therapy or for 1 week following discontinuation of thalidomide.
Bolniki med zdravljenjem ali 1 teden po ukinitvi zdravljenja s talidomidom ne smejo darovati krvi ali sperme.
Patients should not donate blood while taking Erivedge and for 24 months after the final dose.
Bolnice in bolniki med jemanjem zdravila Erivedge in še 24 mesecev po zadnjem odmerku tega zdravila ne smejo darovati krvi.
Patients should not drive or operate machines for at least 1 hour after receiving Ceplene.
Bolniki naj ne vozijo ali upravljajo s stroji vsaj eno uro po uporabi zdravila Ceplene.
Patients should not drive or use machines until their visual function has recovered sufficiently.
Bolniki ne smejo voziti ali upravljati s stroji, dokler se jim vid dovolj ne izboljša.
Patients should not eat for at least two hours before and one hour after their dose of Cabometyx.
Bolniki ne smejo uživati hrane vsaj dve uri preden vzamejo zdravilo Cabometyx, in eno uro po tem.
Patients should not lie down for 1 hour after taking Bondenza.
Po zaužitju zdravila Bondenza bolniki 1 uro ne smejo leči.
Patients should not lie down for 1 hour after taking Bonviva.
Po zaužitju zdravila Bonviva bolniki 1 uro ne smejo leči.
Patients should not lie down for 1 hour after taking Ibandronic Acid Teva.
Bolnik se ne sme uleči še eno uro po tem, ko je vzel zdravilo Ibandronska kislinaTeva.
Patients should not lie down for 60 minutes after taking Bondronat.
Po zaužitju zdravila Bondronat bolniki 60 minut ne smejo leči.
Patients should not lie down for 60 minutes after taking Iasibon.
Po zaužitju zdravila Iasibon bolniki 60 minut ne smejo leči.
Patients should not lie down for 60 minutes after taking Ibandronic acid Sandoz.
Po zaužitju zdravila Ibandronska kislina Sandoz bolniki 60 minut ne smejo leči.
Patients should not lie down for 60 minutes after taking Ibandronic Acid Teva.
Bolnik se ne sme uleči še 60 minut po tem, ko je vzel zdravilo Ibandronska kislina Teva.
Patients should not lie down for at least 30 minutes after taking ADROVANCE and until after the first food of the day.
Bolnik se ne sme uleči še vsaj 30 minut po zaužitju tablete ADROVANCE in dokler ne zaužije prvega dnevnega obroka hrane.
Patients should not lie down for at least 30 minutes after taking FOSAVANCE and until after the first food of the day.
Bolnik se ne sme uleči še vsaj 30 minut po zaužitju tablete FOSAVANCE in dokler ne zaužije prvega dnevnega obroka hrane.
Patients should not lie down for at least 30 minutes after taking VANTAVO and until after the first food of the day.
Bolnik se ne sme uleči še vsaj 30 minut po zaužitju tablete VANTAVO in dokler ne zaužije prvega dnevnega obroka hrane.
Patients should not receive live and live-attenuated vaccines during Raptiva treatment. (See section 4.4).
Med zdravljenjem z Raptivo bolniki ne smejo prejemati živih ali živih oslabljenih cepiv (Glejte poglavje 4.4.).
Patients should not receive live and live-attenuated vaccines while on Raptiva therapy.
Med zdravljenjem z Raptivo bolniki ne smejo prejemati živih ali živih oslabljenih cepiv.
Patients should not start treatment with Lynparza until they have recovered from haematological toxicity caused by previous anticancer therapy (haemoglobin, platelet, and neutrophil levels should be within normal range or CTCAE grade 1).
Bolnice ne smejo začeti zdravljenja z zdravilom Lynparza, dokler ne okrevajo po hematotoksičnih učinkih predhodnega zdravljenja proti raku (koncentracije hemoglobina, trombocitov in nevtrofilcov morajo biti znotraj normalnega območja ali stopnje 1 po CTCAE).
Patients should not stop therapy with fluticasone furoate/vilanterol in asthma or COPD, without physician supervision since symptoms may recur after discontinuation.
Bolniki zdravljenja astme ali KOPB s flutikazonfuroatom/vilanterolom ne smejo končati brez zdravniškega nadzora, ker se lahko simptomi po prenehanju ponovijo.
Patients should not take a double dose to compensate for a missed dose.
Bolnik ne sme vzeti dvojnega odmerka, da bi nadomestil izpuščeni odmerek.
Patients should not take a loading dose of VKA in order to promptly achieve a stable INR between 2 and 3.
Bolniki naj ne vzamejo polnitvenega odmerka VKA, da bi takoj dosegli stabilen INR med 2 in 3.
Patients should not take a second dose within a single night.
Bolniki ne smejo vzeti drugega odmerka v isti noči.
Patients should not take any antacids, dairy products or mineral supplements in the four hours before and in the two hours after taking Revolade.
Štiri ure pred jemanjem zdravila Revolade in dve uri po njem bolniki ne smejo zaužiti antacidov, mlečnih izdelkov ali mineralnih prehranskih dopolnil.
Patients should not take more than four doses a day and should leave a gap of at least four hours between treating each episode of pain.
Bolniki ne smejo prejeti več kot štiri odmerke dnevno, poleg tega pa mora biti med zdravljenjem posamičnih epizod bolečine najmanj štiriurni premor.
Patients should not take more than one capsule in a day.
Bolniki ne smejo vzeti več kot eno kapsulo na dan.
Patients should not take other medicines that lower uric acid levels during Krystexxa treatment, so that the effect of Krystexxa can be clearly judged.
Bolniki med zdravljenjem z zdravilom Krystexxa ne smejo jemati drugih zdravil, ki znižujejo ravni sečne kisline, tako da je mogoče učinek zdravila Krystexxa jasno oceniti.
Patients should not use more than 4 doses per day.
Bolniki ne smejo uporabiti več kot 4 odmerke na dan.
Patients should not wear more than one IONSYS at the same time.
Bolniki ne smejo nositi več kot enega sistema IONSYS naenkrat.